The Advent of More Potent ALK Inhibitors
Alice T. Shaw, MD, PhD, from Massachusetts General Hospital, discusses the advent of more potent ALK inhibitors such as LDK378 and the treatment of ALK-positive lung cancer patients with crizotinib.
Clinical Pearls
Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses the advent of more potent ALK inhibitors and the treatment of ALK-positive lung cancer patients with crizotinib.
- The treatment of these patients is more complicated now, with the advent of more potent ALK inhibitors
- New ALK inhibitors are potent in patients both resistant and naive to crizotinib
- At a large cancer center, the option exists to start crizotinib as standard therapy or consider a clinical trial with a next-generation ALK inhibitor
- In the community setting, standard procedure would be to start a newly-diagnosed ALK-positive patient on crizotinib
Related Videos
Related Content
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024Article
At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
